RxDoctor Payments Data

Mohamed Homsi, MD

Cardiovascular Disease · Avon, INNPI 1952569121

Payments from drug & device makers

$29,186in general payments, 2019–2025

Across 113 payments — averaging $258.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Cook Research Incorporated$13K
  • Medical Device Business Services, Inc.$5K
  • Medtronic$3K
  • Abbott$3K
  • Biosense Webster, Inc.$2K
  • Boston Scientific$2K
  • plus $1K from 9 others

What the payments were for

  • Consulting fees$19,43867%
  • Travel & lodging$4,35615%
  • Food & beverage$5,39318%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$29,186 in reported general payments places this provider in the 80th percentile of 408 cardiovascular disease providers in Indiana.

See all cardiovascular disease providers in Indiana

Medicare billing

Part B allowed, 2024
$203,773
Medicare patients
1,167
Services billed
3,549

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban562$618,871
XareltoRivaroxaban139$170,484
MultaqDronedarone Hcl45$44,342
EntrestoSacubitril/Valsartan30$35,760
Repatha SureclickEvolocumab13$14,554
Flecainide Acetate187$10,951
Metoprolol Succinate386$4,924
Diltiazem 24hr Er (Cd)Diltiazem Hcl115$3,508
Amiodarone Hcl106$3,241
SotalolSotalol Hcl132$2,628
Dofetilide21$2,445
Atorvastatin Calcium134$1,415
Torsemide46$1,356
Potassium Chloride65$1,016
Amlodipine Besylate112$939

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$59$618,871562 claims
Johnson & JohnsonXarelto$156$170,484139 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 408 cardiovascular disease providers in Indiana.

Other cardiovascular disease in Avon

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →